ClinicalTrials.gg
CompletedNCT00697541Updated Feb 18, 2021Results posted

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

A Phase 2 interventional study of 0.18% COL-118 facial gel (1.8 mg brimonidine) and 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in Erythematous Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
10th of 11
20 · median 205
Started
2008
the only one that year
Phase 2
3 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 2, and was the 1st registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%

Read the detailed description

A double-blind, randomized, 2-way crossover, safety, pharmacokinetic/-dynamic (PK/PD) study of 0.18% COL-118 facial gel and 0.2% brimonidine ophthalmic solution administered in male and female patients with moderate to severe erythematous rosacea.

Twenty male and female subjects with moderate to severe erythematous rosacea will be randomized into 2 groups of 10 subjects.

Each group will be randomized to receive 2 treatments (Treatments A and B, in Sequence 1: A/B or Sequence 2: B/A), as follows:

Treatment A: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours;

Treatment B: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.

There will be at least a 1-day washout between dose administrations (Period 1 and Period 2).

Blood samples for PK analysis of brimonidine levels will be collected at the following time points during Period 1 and Period 2: 0 Hour (prior to dose) and at 1, 2, 3, 4 (prior to 2nd dose), 5, 6, 7, and 8 hours post-dose.

03

Conditions studied

  • Erythematous Rosacea

Browse trials for

Keywords

  • erythematous rosacea
  • facial gel
  • brimonidine
  • ophthalmic solution
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age
  • Clinical diagnosis of rosacea
  • A score of ≥ 3 on the CEAS
  • A score of ≥ 3 on the PSA
  • IOP ≥ 10 mm Hg
  • Non-pregnant and non-lactating females

Exclusion criteria

Exclusion Criteria:

  • History of or allergies to any ingredient of the study drugs, unless approved by the Investigator
  • Use of brimonidine prescription medications within 14 days prior to Check-in
  • Use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the Investigator
  • Use of systemic or topical applied to the face 14 days prior to Check in
  • The use of any Rx or OTC products for the treatment of acne or rosacea within 14 days prior to check in
  • The use of isotretinoin within 180 days prior to check in
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    A

    One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours

    Drug: 0.18% COL-118 facial gel (1.8 mg brimonidine) · Drug: Advanced Eye Relief

  • Active comparator
    B

    One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically

    Drug: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) · Drug: COL-118 facial gel vehicle

Interventions

  • One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours

    Also known as: brimonidine

  • Drug0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)

    Drug page: Brimonidine

    One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.

    Also known as: brimonidine tartrate/drop

  • DrugAdvanced Eye Relief

    One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours

  • DrugCOL-118 facial gel vehicle

    One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Systemic Concentration of Brimonidine

    Maximum observed plasma concentration

    Time frame: 0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose

  2. AUC - Area Under the Curve of Brimonidine

    Area under the plasma concentration-time curve from 0 hour to the last measurable plasma concentration, calculated by the linear trapezoidal method After two topical applications of 0.18% COL-118 facial gel, plasma levels of brimonidine for all subjects were below the LoQ (25 pg/mL), with the exception of one single outlier value. Thus, no PK analysis could be performed for 0.18% COL-118 facial gel. After ocular administration of 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations of brimonidine were observed in 11 of the 18 subjects who received the brimonidine tartrate ophthalmic solution. Brimonidine rapidly appeared in plasma The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects The mean AUC0-t also was not calculated.

    Time frame: 0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose

  3. Tmax - Time to Maximum Plasma Concentration

    time to maximum plasma concentration

    Time frame: 0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose

07

Results

Posted Aug 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneSeq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine DropsSeq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline Drops
Started1010
Completed89
Not completed21

Outcome measures

PrimaryCmax - Maximum Systemic Concentration of Brimonidine

Maximum observed plasma concentration

Time frame:
0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose
Reported as:
Mean · pg/mL
Cmax - Maximum Systemic Concentration of Brimonidine
pg/mLTreatment A - COL-118 Facial Gel + Saline DropsTreatment B - Vehicle Gel + Brimonidine Drops
Cmax - Maximum Systemic Concentration of BrimonidineNA ± NANA ± NA
PrimaryAUC - Area Under the Curve of Brimonidine

Area under the plasma concentration-time curve from 0 hour to the last measurable plasma concentration, calculated by the linear trapezoidal method After two topical applications of 0.18% COL-118 facial gel, plasma levels of brimonidine for all subjects were below the LoQ (25 pg/mL), with the exception of one single outlier value. Thus, no PK analysis could be performed for 0.18% COL-118 facial gel. After ocular administration of 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations of brimonidine were observed in 11 of the 18 subjects who received the brimonidine tartrate ophthalmic solution. Brimonidine rapidly appeared in plasma The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects The mean AUC0-t also was not calculated.

Time frame:
0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose
Reported as:
Mean · pg*hr/mL
AUC - Area Under the Curve of Brimonidine
pg*hr/mLTreatment A - COL-118 Gel + Saline DropsTreatment B - Vehicle Gel + Brimonidine Drops
AUC - Area Under the Curve of BrimonidineNA ± NANA ± NA
PrimaryTmax - Time to Maximum Plasma Concentration

time to maximum plasma concentration

Time frame:
0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose
Reported as:
Mean · Hours
Tmax - Time to Maximum Plasma Concentration
HoursTreatment A - COL-118 Facial Gel + Saline DropsTreatment B - Vehicle Gel + Brimonidine Drops
Tmax - Time to Maximum Plasma ConcentrationNA (NA to NA)NA (0.933 to 4.07)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/19 (0%)3/19 (15.8%)
Treatment B—0/18 (0%)7/18 (38.9%)
Most frequent other events
Most frequent other events
EventTreatment ATreatment B
HeadacheNervous system disorders3/195/18
SyncopeNervous system disorders0/191/18
pharyngolagyngeal painRespiratory, thoracic and mediastinal disorders0/191/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine DropsSeq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline DropsTotal
<=18 years000
Between 18 and 65 years101020
>=65 years000
Age, Continuous
Age, Continuous(years)Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine DropsSeq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline DropsTotal
Mean43.0 ± 8.547.1 ± 6.745.1 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine DropsSeq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline DropsTotal
Female101020
Male000
Region of Enrollment
Region of Enrollment(participants)Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine DropsSeq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline DropsTotal
United States101020
08

Study locations

1 site
  • KGL, Inc.
    Broomall, Pennsylvania 19008, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 6 years 2 months after primary completion. A results delay was requested in Oct 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 16, 2008
Start
May 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results delay requested
Oct 16, 2010
Results first posted
Aug 7, 2014
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00697541
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 16, 2008
Start date
May 2008
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Aug 7, 2014
Last update
Feb 18, 2021

Study contacts

James Leyden, M.D.
principal investigator · KGL, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion